ARIAN protocol: a phase III study of sacituzumab and zimberelimab for the treatment of patients with non-small cell lung cancer
Autores de IIS La Fe
Participantes ajenos a IIS La Fe
- Provencio M.
- Aguiar D.
- Antoñanzas M.
- Areses M.C.
- Azkárate A.
- Barba A.
- Bernabé R.
- Blanco R.
- Borregón M.
- Campos B.
- Coves J.
- de Castro J.
- Domènech M.
- Dómine M.
- García Campelo R.
- Lucía-Gozálvez C.
- Lázaro-Quintela M.
- Insa A.
- López Castro R.
- Martínez-Marti A.
- Medina S.
- Moreno M.Á.
- Nadal E.
- Olivares-Hernández A.
- Reguart N.
- Sala M.Á.
- Medina K.
- Vila L.
- Massutí B.
Grupos
Abstract
Lung cancer remains the leading cause of cancer-related deaths worldwide. Despite advances to improve treatment in resectable early-stage and locally advanced non-small cell lung cancer (NSCLC), survival rates after 5 years remain low, with a high risk of disease progression. Patients who fail to achieve a pathological complete response (pCR) after neoadjuvant treatment have unfavorable outcomes. ARIAN is a phase III, multicenter, open-label, randomized trial evaluating adjuvant treatment in adults with stage IB-IIIB (N2) NSCLC who have undergone neoadjuvant chemo-immunotherapy but did not achieve pCR after completing surgical resection. Patients will be stratified based on programmed death receptor-ligand 1 (PD-L1) tumor expression and randomized (1:1:1) to observation for 10 months (Arm 1), zimberelimab for 13 cycles (Arm 2), or sacituzumab govitecan and zimberelimab for 8 cycles followed by zimberelimab monotherapy for 5 cycles (Arm 3). The primary endpoint is disease-free survival, and secondary endpoints include overall survival and safety. © 2026 Informa UK Limited, trading as Taylor & Francis Group.
Datos de la publicación
- ISSN/ISSNe:
- 1471-2598, 1744-7682
- Tipo:
- Article
- Páginas:
- 441-449
- PubMed:
- 42159280
- Enlace a otro recurso:
- www.scopus.com
- Factor de Impacto:
- 1,001 SCImago ℠
- Cuartil:
- Q1 SCImago ℠
EXPERT OPINION ON BIOLOGICAL THERAPY TAYLOR & FRANCIS LTD
Documentos
- No hay documentos
Filiaciones
Keywords
- Antibodies, Monoclonal, Humanized; Camptothecin; Carcinoma, Non-Small-Cell Lung; Humans; Immunoconjugates; Lung Neoplasms; sacituzumab govitecan; zimberelimab; antibody conjugate; camptothecin; monoclonal antibody; sacituzumab govitecan; adjuvant therapy; adult; alopecia; anemia; Article; cancer immunotherapy; chemoimmunotherapy; computer assisted tomography; conservative treatment; constipation; controlled study; disease free survival; drug withdrawal; ECOG Performance Status; event free survival; fatigue; female; good clinical practice; human; hyperthyroidism; hypothyroidism; immune response; laboratory test; major clinical study; male; nausea; neoadjuvant therapy; neutropenia; non small cell lung cancer; overall survival; pathological complete response; phase 3 clinical trial; physical examination; postoperative period; vomiting; clinical trial; drug therapy; lung tumor; non small cell lung cancer; pathology
Cita
Provencio M,Aguiar D,Antoñanzas M,Areses MC,Azkárate A,Barba A,Bernabé R,Blanco R,Borregón M,Campos B,Coves J,de Castro J,Domènech M,Dómine M,García R,Lucía C,Lázaro M,Insa A,JUAN Ó,López R,Martínez A,Medina S,Moreno MÁ,Nadal E,Olivares A,Reguart N,Sala MÁ,Medina K,Vila L,Massutí B. ARIAN protocol: a phase III study of sacituzumab and zimberelimab for the treatment of patients with non-small cell lung cancer. Expert Opin. Biol. Ther. 2026. 26. (5):p. 441-449. IF:4,000. (2).
Portal de investigación